IP Library › Granted Patent US 12,577,305
Granted Patent B2
US 12,577,305 · App. 17/417,480 · Granted Mar 17, 2026

Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof

Inventors: Zhihua Huang (Shanghai, CN); Wuzhong Shen (Shanghai, CN); Yiqun Rao (Shanghai, CN); Yumin Cui (Shanghai, CN); Xiaoqiang Yan (Shanghai, CN)
Assignee: ITabMed (HK) Limited
C07K16/2809A61P35/00A61P35/02C07K16/2803A61K2039/505C07K2317/31C07K2317/522C07K2317/55C07K2317/56C07K2317/622C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,577,305
App. No.
17/417,480
Granted
Mar 17, 2026
Kind
B2
Abstract

Provided are multispecific antigen binding proteins (MSAPs) that specifically bind to CD3 and CD19. Further provided are uses of the MSAPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSAPs.

Claims (56)

1 . A multispecific antigen binding protein comprising:

(I) an anti-CD3 Fab fragment that specifically binds to CD3, wherein the anti-CD3 Fab fragment comprises:

(a) an immunoglobulin (Ig) heavy chain variable region (VH) and an Ig heavy chain constant region (CH1); and

(b) an Ig light chain variable region (VL) and an Ig light chain constant region (CL);

(II) an anti-CD19 single chain variable fragment (scFv) that specifically binds to CD19,

wherein the anti-CD19 scFv comprises a VH, wherein the VH of the anti-CD19 scFv comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and

wherein the anti-CD19 scFv comprises a VL, wherein the VL of the anti-CD19 scFv comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 48, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 49; and

(III) an optional linker connecting the anti-CD3 Fab fragment and the anti-CD19 scFv; and

wherein:

(i) the anti-CD19 scFv is connected to the N-terminus of the VH or the VL of the anti-CD3 Fab fragment; or

(ii) the multispecific antigen binding protein comprises a first anti-CD19 scFv and a second anti-CD19 scFv, wherein the first anti-CD19 scFv is fused to the N-terminus of the VH of the anti-CD3 Fab fragment, and wherein the second anti-CD19 scFv is fused to the N-terminus of the VL of the anti-CD3 Fab fragment.

2 . The multispecific antigen binding protein of claim 1 , wherein the anti-CD19 scFv is fused to the N-terminus of the VH of the anti-CD3 Fab fragment.

3 . The multispecific antigen binding protein of claim 1 , wherein the anti-CD19 scFv is fused to the N-terminus of the VL of the anti-CD3 Fab fragment.

4 . The multispecific antigen binding protein of claim 1 , wherein the multispecific antigen binding protein comprises a first anti-CD19 scFv and a second anti-CD19 scFv, wherein the first anti-CD19 scFv is fused to the N-terminus of the VH of the anti-CD3 Fab fragment, and wherein the second anti-CD19 scFv is fused to the N-terminus of the VL of the anti-CD3 Fab fragment.

5 . The multispecific antigen binding protein of claim 4 , wherein the VH of the anti-CD3 Fab fragment comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11; and wherein the VL of the anti-CD3 Fab fragment comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.

6 . The multispecific antigen binding protein of claim 5 , wherein the first anti-CD19 scFv and the second anti-CD19 scFv have the same amino acid sequence.

7 . The multispecific antigen binding protein of claim 6 , wherein the first anti-CD19 scFv and the second anti-CD19 scFv each comprises the amino acid sequence of SEQ ID NO: 51.

8 . The multispecific antigen binding protein of claim 4 , wherein the VH of the first anti-CD19 scFv and the VH of the second anti-CD19 scFv each comprises the amino acid sequence of SEQ ID NO: 7, and wherein the VL of the first anti-CD19 scFv and the VL of the second anti-CD19 scFv each comprises the amino acid sequence of SEQ ID NO: 50.

9 . The multispecific antigen binding protein of claim 4 , wherein the first anti-CD19 scFv and the second anti-CD19 scFv have the same amino acid sequence.

10 . The multispecific antigen binding protein of claim 1 , wherein the VH of the anti-CD3 Fab fragment comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11; and wherein the VL of the anti-CD3 Fab fragment comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.

11 . The multispecific antigen binding protein of claim 10 , wherein the VH of the anti-CD3 Fab fragment comprises the amino acid sequence of SEQ ID NO: 15; and wherein the VL of the anti-CD3 Fab fragment comprises the amino acid sequence of SEQ ID NO: 16.

12 . The multispecific antigen binding protein of claim 11 , wherein the anti-CD3 Fab fragment comprises a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 57, and a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 58.

13 . The multispecific antigen binding protein of claim 12 , wherein:

i) the multispecific antigen binding protein comprises an anti-CD19 scFv connected to the N-terminus of the VH of the anti-CD3 Fab fragment via a linker to form a first polypeptide of the multispecific antigen binding protein, wherein the first polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 53, and wherein the multispecific antigen binding protein comprises a second polypeptide comprising the amino acid sequence of SEQ ID NO: 58; or

ii) the multispecific antigen binding protein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 57, wherein the multispecific antigen binding protein comprises an anti-CD19 scFv connected to the N-terminus of the VL of the anti-CD3 Fab fragment via a linker to form a second polypeptide of the multispecific antigen binding protein, and wherein the second polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 54.

14 . The multispecific antigen binding protein of claim 12 , wherein the anti-CD19 scFv, or the first anti-CD19 scFv and/or the second anti-CD19 scFv, comprises the amino acid sequence of SEQ ID NO: 51.

15 . The multispecific antigen binding protein of claim 1 , wherein the VH of the anti-CD19 scFv, or the VH of the first anti-CD19 scFv and/or the second anti-CD19 scFv, comprises the amino acid sequence of SEQ ID NO: 7; and wherein the VL of the anti-CD19 scFv, or the VL of the first anti-CD19 scFv and/or the second anti-CD19 scFv, comprises the amino acid sequence of SEQ ID NO: 50.

16 . The multispecific antigen binding protein of claim 1 , wherein the anti-CD19 scFv, or the first anti-CD19 scFv and/or the second anti-CD19 scFv, comprises the amino acid sequence of SEQ ID NO: 51.

17 . The multispecific antigen binding protein of claim 1 , wherein the linker comprises the amino acid sequence of any one of SEQ ID NOs: 20-22, 29, and 31-44.

18 . An isolated nucleic acid encoding the multispecific antigen binding protein of claim 1 .

19 . A pharmaceutical composition comprising the multispecific antigen binding protein of claim 1 , and optionally a pharmaceutically acceptable carrier.

20 . A method of treating a CD19-positive cancer in an individual, comprising administering to the individual an effective amount of the pharmaceutical composition of claim 19 .

21 . The method of claim 20 , wherein the CD19-positive cancer is selected from the group consisting of acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), acute B lymphoblastic leukemia (B-ALL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma, systemic mastocytosis, and Burkitt's lymphoma.

22 . A multispecific antigen binding protein comprising:

(I) an anti-CD3 Fab fragment that specifically binds to CD3, wherein the anti-CD3 Fab fragment comprises:

(a) a VH and a CH1; and

(b) a VL and a CL;

(II) a first anti-CD19 scFv and a second anti-CD19 scFv; and

(III) a first linker and a second linker;

wherein the first anti-CD19 scFv is fused to the N-terminus of the VH of the anti-CD3 Fab fragment via the first linker to form a first polypeptide of the multispecific antigen binding protein, and the second anti-CD19 scFv is fused to the N-terminus of the VL of the anti-CD3 Fab fragment via the second linker to form a second polypeptide of the multispecific antigen binding protein;

wherein the first polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 53, and wherein the second polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 54.

23 . A pharmaceutical composition comprising the multispecific antigen binding protein of claim 22 , and optionally a pharmaceutically acceptable carrier.

24 . A multispecific antigen binding protein comprising:

(I) an anti-CD3 Fab fragment that specifically binds to CD3, wherein the anti-CD3 Fab fragment comprises:

(a) a VH and a CH1; and

(b) a VL and a CL;

(II) a first anti-CD19 scFv and a second anti-CD19 scFv; and

(III) a first linker and a second linker;

wherein the first anti-CD19 scFv is fused to the N-terminus of the VH of the anti-CD3 Fab fragment via the first linker to form a first polypeptide of the multispecific antigen binding protein, and the second anti-CD19 scFv is fused to the N-terminus of the VL of the anti-CD3 Fab fragment via the second linker to form a second polypeptide of the multispecific antigen binding protein;

wherein the first polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 60, and wherein the second polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 61.

25 . A pharmaceutical composition comprising the multispecific antigen binding protein of claim 24 , and optionally a pharmaceutically acceptable carrier.

26 . A multispecific antigen binding protein, wherein:

i) the multispecific antigen binding protein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 57, wherein the multispecific antigen binding protein comprises an anti-CD19 scFv connected to the N-terminus of the VL of an anti-CD3 Fab fragment via a linker to form a second polypeptide of the multispecific antigen binding protein, wherein the second polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 61;

ii) the multispecific antigen binding protein comprises an anti-CD19 scFv connected to the N-terminus of the VH of an anti-CD3 Fab fragment via a linker to form a first polypeptide of the multispecific antigen binding protein, wherein the first polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 60, and wherein the multispecific antigen binding protein comprises a second polypeptide comprising the amino acid sequence of SEQ ID NO: 58;

iii) the multispecific antigen binding protein comprises a first anti-CD19 scFv connected to the N-terminus of the VH of an anti-CD3 Fab fragment via a first linker to form a first polypeptide of the multispecific antigen binding protein, wherein the first polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 53, wherein the multispecific antigen binding protein comprises a second anti-CD19 scFv connected to the N-terminus of the VL of the anti-CD3 Fab fragment via a second linker to form a second polypeptide of the multispecific antigen binding protein, and wherein the second polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 61; or

iv) the multispecific antigen binding protein comprises an anti-CD19 scFv connected to the N-terminus of the VH of an anti-CD3 Fab fragment via a first linker to form a first polypeptide of the multispecific antigen binding protein, wherein the first polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 60, wherein the multispecific antigen binding protein comprises a second anti-CD19 scFv connected to the N-terminus of the VL of the anti-CD3 Fab fragment via a second linker to form a second polypeptide of the multispecific antigen binding protein, and wherein the second polypeptide of the multispecific antigen binding protein comprises the amino acid sequence of SEQ ID NO: 54.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2026
From: ITABMED (HK) LIMITED
To: ITABMED CO., LTD.
Reel/Frame 074003/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2021
From: HUANG, ZHIHUA; SHEN, WUZHONG; RAO, YIQUN; CUI, YUMIN; YAN, XIAOQIANG
To: EVIVE BIOTECHNOLOGY (SHANGHAI) LTD
Reel/Frame 056773/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2021
From: EVIVE BIOTECHNOLOGY (SHANGHAI) LTD
To: EVIVE BIOTECH LTD.
Reel/Frame 056748/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2021
From: EVIVE BIOTECH LTD.
To: ITABMED (HK) LIMITED
Reel/Frame 056748/0761 →
CHANGE OF NAME Recorded Jul 2, 2021
From: GENERON (SHANGHAI) CORPORATION LTD.
To: EVIVE BIOTECHNOLOGY (SHANGHAI) LTD
Reel/Frame 056758/0836 →
Priority Claims (1)
WO PCT/CN2018/123108 · Dec 24, 2018 · international
Continuity (1)
Related Publication 20220064295A1 · Mar 3, 2022
References Cited (400)
US 4237224A · Cohen et al. · 1980 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5030719A · Umemoto et al. · 1991 [cited by applicant]
US 5151510A · Stec et al. · 1992 [cited by applicant]
US 5283173A · Fields et al. · 1994 [cited by applicant]
US 5468614A · Fields et al. · 1995 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5612205A · Kay et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5625825A · Rostoker et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5643763A · Dunn et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693792A · Torii et al. · 1997 [cited by applicant]
US 5703057A · Johnston et al. · 1997 [cited by applicant]
US 5714350A · Co et al. · 1998 [cited by applicant]
US 5721367A · Kay et al. · 1998 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5736137A · Anderson et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5777085A · Co et al. · 1998 [cited by applicant]
US 5789215A · Berns et al. · 1998 [cited by applicant]
US 5789650A · Lonberg et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5837458A · Minshull et al. · 1998 [cited by applicant]
US 5874299A · Lonberg et al. · 1999 [cited by applicant]
US 5877397A · Lonberg et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5959083A · Bosslet et al. · 1999 [cited by applicant]
US 6005079A · Casterman et al. · 1999 [cited by applicant]
US 6023010A · Krimpenfort et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6162963A · Kucherlapati et al. · 2000 [cited by applicant]
US 6255458B1 · Lonberg et al. · 2001 [cited by applicant]
US 6291158B1 · Winter et al. · 2001 [cited by applicant]
US 6291161B1 · Lerner et al. · 2001 [cited by applicant]
US 6326193B1 · Liu · 2001 [cited by applicant]
US 6410319B1 · Raubitschek et al. · 2002 [cited by applicant]
US 6423498B1 · Markland et al. · 2002 [cited by applicant]
US 6521404B1 · Griffiths et al. · 2003 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7087409B2 · Barbas et al. · 2006 [cited by applicant]
US 7109003B2 · Hanson et al. · 2006 [cited by applicant]
US 7115717B2 · Mori et al. · 2006 [cited by applicant]
US 7288251B2 · Bedian et al. · 2007 [cited by applicant]
US 7387776B2 · Keler et al. · 2008 [cited by applicant]
US 7429644B2 · Garber et al. · 2008 [cited by applicant]
US 7435797B2 · Lowman et al. · 2008 [cited by applicant]
US 7446191B2 · Jensen · 2008 [cited by applicant]
US 7462352B2 · Hansen et al. · 2008 [cited by applicant]
US 7514537B2 · Jensen · 2009 [cited by applicant]
US 7557189B2 · Hoffee et al. · 2009 [cited by applicant]
US 7723482B2 · Soulillou et al. · 2010 [cited by applicant]
US 7723484B2 · Beidler et al. · 2010 [cited by applicant]
US 7846440B2 · Schoeberl et al. · 2010 [cited by applicant]
US 8101179B2 · Numazaki et al. · 2012 [cited by applicant]
US 8236308B2 · Kischel et al. · 2012 [cited by applicant]
US 8709421B2 · Heiss et al. · 2014 [cited by applicant]
US 8784821B1 · Kufer · 2014 [cited by applicant]
US 8846042B2 · Zhou · 2014 [cited by applicant]
US 8884602B2 · Utsunomiya · 2014 [cited by applicant]
US 9718893B2 · Jung · 2017 [cited by applicant]
US 10428155B2 · Moore et al. · 2019 [cited by applicant]
US 10870701B2 · Cui et al. · 2020 [cited by applicant]
US 11013800B2 · Zhou · 2021 [cited by applicant]
US 11304975B2 · Galetto et al. · 2022 [cited by applicant]
US 11987633B2 · Kufer et al. · 2024 [cited by applicant]
US 20020086014A1 · Korman et al. · 2002 [cited by applicant]
US 20020142359A1 · Copley et al. · 2002 [cited by applicant]
US 20030157054A1 · Gillies et al. · 2003 [cited by applicant]
US 20050033029A1 · Lu · 2005 [cited by applicant]
US 20050112694A1 · Carter et al. · 2005 [cited by applicant]
US 20050118183A1 · Hoffee et al. · 2005 [cited by applicant]
US 20050208043A1 · Adams et al. · 2005 [cited by applicant]
US 20050232919A1 · Grasso et al. · 2005 [cited by applicant]
US 20060165686A1 · Elson et al. · 2006 [cited by applicant]
US 20060177896A1 · Mach et al. · 2006 [cited by applicant]
US 20070059298A1 · Volkmann · 2007 [cited by applicant]
US 20070065431A1 · Coia et al. · 2007 [cited by applicant]
US 20070077246A1 · Koenig et al. · 2007 [cited by applicant]
US 20070148718A1 · Medghalchi et al. · 2007 [cited by applicant]
US 20070161783A1 · Barbosa et al. · 2007 [cited by applicant]
US 20070274981A1 · Sun et al. · 2007 [cited by applicant]
US 20070287170A1 · Davis et al. · 2007 [cited by applicant]
US 20080044429A1 · Johnson et al. · 2008 [cited by applicant]
US 20080260731A1 · Bernett · 2008 [cited by examiner]
US 20080286272A1 · Lackmann et al. · 2008 [cited by applicant]
US 20090136485A1 · Chu · 2009 [cited by applicant]
US 20090155275A1 · Wu et al. · 2009 [cited by applicant]
US 20090191201A1 · Heiss et al. · 2009 [cited by applicant]
US 20090202433A1 · Chang et al. · 2009 [cited by applicant]
US 20090220501A1 · Fey · 2009 [cited by applicant]
US 20090232810A1 · Kraus et al. · 2009 [cited by applicant]
US 20090304710A1 · Park et al. · 2009 [cited by applicant]
US 20090304716A1 · Reinhardt et al. · 2009 [cited by applicant]
US 20100003253A1 · Laeremans et al. · 2010 [cited by applicant]
US 20100003258A1 · Weng et al. · 2010 [cited by applicant]
US 20100025177A1 · Fukushima et al. · 2010 [cited by applicant]
US 20100065818A1 · Kim et al. · 2010 [cited by applicant]
US 20100092491A1 · Anastasi et al. · 2010 [cited by applicant]
US 20100150918A1 · Kufer et al. · 2010 [cited by applicant]
US 20100183615A1 · Kufer et al. · 2010 [cited by applicant]
US 20100189722A1 · Heider et al. · 2010 [cited by applicant]
US 20100196364A1 · Kim et al. · 2010 [cited by applicant]
US 20100226922A1 · Maetzel et al. · 2010 [cited by applicant]
US 20100239582A1 · Humphreys et al. · 2010 [cited by applicant]
US 20100310463A1 · Gunnarsson et al. · 2010 [cited by applicant]
US 20110028696A1 · Cardarelli et al. · 2011 [cited by applicant]
US 20110054151A1 · Lazar et al. · 2011 [cited by applicant]
US 20110059090A1 · Revets et al. · 2011 [cited by applicant]
US 20110064653A1 · Hansen et al. · 2011 [cited by applicant]
US 20110123529A1 · Laeremans et al. · 2011 [cited by applicant]
US 20120135110A1 · Chiba et al. · 2012 [cited by applicant]
US 20120244161A1 · Zugmeier et al. · 2012 [cited by applicant]
US 20120288275A1 · Zhang · 2012 [cited by applicant]
US 20120321626A1 · Zhou · 2012 [cited by applicant]
US 20150056206A1 · Zhou · 2015 [cited by applicant]
US 20150086550A1 · Heiss et al. · 2015 [cited by applicant]
US 20170174786A1 · Bacac et al. · 2017 [cited by applicant]
US 20190092862A1 · Cui et al. · 2019 [cited by applicant]
US 20190284279A1 · Kong et al. · 2019 [cited by applicant]
US 20200172627A1 · Bacac et al. · 2020 [cited by applicant]
US 20210070882A1 · Bacac et al. · 2021 [cited by applicant]
US 20210102001A1 · Zhou et al. · 2021 [cited by applicant]
US 20210214440A1 · Ganesan et al. · 2021 [cited by applicant]
US 20210301018A1 · Huang et al. · 2021 [cited by applicant]
US 20210393776A1 · Zhou et al. · 2021 [cited by applicant]
CN 101687915A · 2010 [cited by applicant]
CN 103842383A · 2014 [cited by applicant]
CN 104203981A · 2014 [cited by applicant]
CN 104592391A · 2015 [cited by applicant]
CN 104788567A · 2015 [cited by applicant]
CN 105378068A · 2016 [cited by applicant]
CN 107184977A · 2017 [cited by applicant]
CN 107636015A · 2018 [cited by applicant]
CN 107660151A · 2018 [cited by applicant]
CN 107903324A · 2018 [cited by applicant]
CN 108026177A · 2018 [cited by applicant]
CN 108690138A · 2018 [cited by applicant]
CN 110603266A · 2019 [cited by applicant]
CN 111484555A · 2020 [cited by applicant]
CN 111655733A · 2020 [cited by applicant]
CN 112794916A · 2021 [cited by applicant]
EP 0183070A2 · 1986 [cited by applicant]
EP 0244234A2 · 1987 [cited by applicant]
EP 0402226A1 · 1990 [cited by applicant]
EP 0463151B1 · 1996 [cited by applicant]
EP 0773288A2 · 1997 [cited by applicant]
EP 0546073B1 · 1997 [cited by applicant]
EP 0843961B1 · 2007 [cited by applicant]
JP 3068180B2 · 2000 [cited by applicant]
JP 3068506B2 · 2000 [cited by applicant]
JP 3068507B2 · 2000 [cited by applicant]
JP 2008539177A · 2008 [cited by applicant]
JP 2009511521A · 2009 [cited by applicant]
JP 2009131284A · 2009 [cited by applicant]
JP 2009526770A · 2009 [cited by applicant]
JP 2010524435A · 2010 [cited by applicant]
JP 2010523096A · 2010 [cited by applicant]
JP 2011501671A · 2011 [cited by applicant]
JP 2014519322A · 2014 [cited by applicant]
JP 2015502373A · 2015 [cited by applicant]
JP 6400470B2 · 2018 [cited by applicant]
JP 2018533929A · 2018 [cited by applicant]
JP 7229566B2 · 2023 [cited by applicant]
WO WO199100360A1 · 1991 [cited by applicant]
WO WO199110741A1 · 1991 [cited by applicant]
WO WO199201047A1 · 1992 [cited by applicant]
WO WO199203918A1 · 1992 [cited by applicant]
WO WO199222645A1 · 1992 [cited by applicant]
WO WO199222647A1 · 1992 [cited by applicant]
WO WO199222670A1 · 1992 [cited by applicant]
WO WO199308829A1 · 1993 [cited by applicant]
WO WO199312227A1 · 1993 [cited by applicant]
WO WO199400569A1 · 1994 [cited by applicant]
WO WO199402602A1 · 1994 [cited by applicant]
WO WO199404678A1 · 1994 [cited by applicant]
WO WO199409131A1 · 1994 [cited by applicant]
WO WO199411026A2 · 1994 [cited by applicant]
WO WO199425585A1 · 1994 [cited by applicant]
WO WO199425591A1 · 1994 [cited by applicant]
WO WO199522618A1 · 1995 [cited by applicant]
WO WO199614436A1 · 1996 [cited by applicant]
WO WO199627011A1 · 1996 [cited by applicant]
WO WO199633735A1 · 1996 [cited by applicant]
WO WO199634096A1 · 1996 [cited by applicant]
WO WO199634103A1 · 1996 [cited by applicant]
WO WO199713852A1 · 1997 [cited by applicant]
WO WO199824884A1 · 1998 [cited by applicant]
WO WO199824893A2 · 1998 [cited by applicant]
WO WO199937791A1 · 1999 [cited by applicant]
WO WO2000076310A1 · 2000 [cited by applicant]
WO 200129058A1 · 2001 [cited by applicant]
WO 200196584A2 · 2001 [cited by applicant]
WO WO2002077029A2 · 2002 [cited by applicant]
WO WO2006072620A1 · 2006 [cited by applicant]
WO WO2006095164A1 · 2006 [cited by applicant]
WO WO2006106959A1 · 2006 [cited by applicant]
WO WO2006114115A1 · 2006 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2007065027A2 · 2007 [cited by applicant]
WO WO2007098934A1 · 2007 [cited by applicant]
WO WO2008024188A2 · 2008 [cited by applicant]
WO WO2008119566A2 · 2008 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009052081A2 · 2009 [cited by applicant]
WO WO2009068628A1 · 2009 [cited by applicant]
WO WO2009068630A1 · 2009 [cited by applicant]
WO WO2009149185A2 · 2009 [cited by applicant]
WO WO2010037836A2 · 2010 [cited by applicant]
WO WO2010037838A2 · 2010 [cited by applicant]
WO WO2010052014A1 · 2010 [cited by applicant]
WO WO2010069765A1 · 2010 [cited by applicant]
WO WO2010104949A2 · 2010 [cited by applicant]
WO WO2010145792A1 · 2010 [cited by applicant]
WO WO2010150918A1 · 2010 [cited by applicant]
WO 2011033105A1 · 2011 [cited by applicant]
WO WO2011028683A1 · 2011 [cited by applicant]
WO WO2011079283A1 · 2011 [cited by applicant]
WO WO2012158818A2 · 2012 [cited by applicant]
WO WO2014012085A2 · 2014 [cited by applicant]
WO 2014110601A1 · 2014 [cited by applicant]
WO WO2014167022A1 · 2014 [cited by applicant]
WO WO2016055593A1 · 2016 [cited by applicant]
WO WO2016142314A1 · 2016 [cited by applicant]
WO WO2016189014A1 · 2016 [cited by applicant]
WO WO2017055314A1 · 2017 [cited by applicant]
WO WO2017157305A1 · 2017 [cited by applicant]
WO WO2018188612A1 · 2018 [cited by applicant]
WO WO2020048525A1 · 2020 [cited by applicant]
WO WO2020135335A1 · 2020 [cited by applicant]
WO 2024188355A1 · 2024 [cited by applicant]
WO 2025185760A1 · 2025 [cited by applicant]
Janeway, 2001, Immunbiology, The generation of diversity in immunoglobulins. [cited by examiner]
Townsend et al., 2016, Front. Immunol. vol. 7: 1-12. [cited by examiner]
Rabia et al. 2018, Biochem. Eng. J. vol. 137: 365-374. [cited by examiner]
Cui, Y. et al. (Nov. 29, 2018). “CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format”, Blood, American Society of Hematology 132(Supp. 1):4169, 2 pages. [cited by applicant]
Houdebine, L. M. (2009). “Production Of Pharmaceutical Proteins by Transgenic Animals,” Comparative Immunology, Microbiology And Infectious Diseases 32(2):107-121. [cited by applicant]
Spiess, C. et al. (2015, e-pub. Jan. 27, 2015). “Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies,” Molecular Immunology 67(2):95-106. [cited by applicant]
Adams, et al. (2006, e-pub. Mar. 6, 2006). “Avidity-Mediated Enhancement of In vivo Tumor Targeting By Single-Chain Fv Dimers,” Clin. Cancer Res. 12:1599-1605. [cited by applicant]
Adams, R.L.P. (Jul. 1969). “The Effect of Endogenous Pools of Thymidylate on the Apparent Rate of DNA Synthesis,” Exp. Cell Res. 56(1):55-58. [cited by applicant]
Alarcon, B. et al. (Apr. 1991). “The CD3-γ And CD3-δ Subunits of the T Cell Antigen Receptor can be Expressed Within Distinct Functional TCR/CD3 Complexes,” EMBO J. 10(4):903-912. [cited by applicant]
Alt, M. et al. (1999). “Novel Tetravalent And Bispecific IgG-Like Antibody Molecules Combining Single-Chain Diabodies With The Immunoglobulin γ1 Fc or CH3 region,” FEES Letters 454:90-94. [cited by applicant]
Altschul, S.F. et al. (1990). “Basic Local Alignment Search Tool,” J. Mol. Biol. 215(3):403-410. [cited by applicant]
Altschul, S.F. et al. (1997). “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucl. Acids Res. 25(17):3389-3402. [cited by applicant]
Amann, M. et al. (Jan. 1, 2008) “Therapeutic Window Of MuS110, A Single-Chain Antibody Construct Bispecific For Murine EpCAM and Murine CD3.” Cancer Res. 68(1):143-151, 10 pages. [cited by applicant]
Anasetti, C. et al. (Dec. 1990). “Induction of Specific Nonresponsiveness in Unprimed Human T Cells by Anti-CD3 Antibody and Alloantigen,” J. Exp. Med. 172(6):1691-1700. [cited by applicant]
Baldrick, P. (Oct. 2000). “Pharmaceutical Excipient Development: The Need For Preclinical Guidance,” Regul. Toxicol Phaimacol. 32(2):210-218. [cited by applicant]
Bargou, R. et al. (Aug. 15, 2008). “Tumor Regression In Cancer Patients By Very Low Doses Of A T Cell-Engaging Antibody,” Science 321(5981):974-977. (English Abstract Only). [cited by applicant]
Baxevanis, C. N. (2008). “Antibody-Based Cancer Therapy,” Expert Opinion On Drug Discovery 3(4):441-452. [cited by applicant]
Beiboer, S.H.W. et al. (2000). “Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics Yet Structural Divergence Between the Original Murine Antibody and its Human Equivalent,” J. … [cited by applicant]
Bellone, S. et al (Jan. 2016). “Solitomab, an EpCAM/CD3 Bispecific Antibody Construct (BITE), is Highly Active Against Primary Uterine Serous Papillary Carcinoma Cell Lines in Vitro”, American Journal Of Obstetrics & Gy… [cited by applicant]
Bendig, M. M. (1995). “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,” Methods: A Companion to Methods in Enzymology 8:83-93. [cited by applicant]
Berger, C. et al. (Jan. 2008; e-pub. Dec. 3, 2007). “Adoptive Transfer of Effector CD8+ T Cells Derived From Central Memory Cells Establishes Persistent T Cell Memory in Primates,” J. Clinical Investigation 118(1):294-3… [cited by applicant]
Beverley, P.C. et al. (Apr. 1981). “Distinctive Functional Characteristics of Human “T” Lymphocytes Defined by E Rosetting or a Monoclonal Anti-T Cell Antibody,” Eur. J. Immunol. 11(4):329-334. [cited by applicant]
Biotecnol. “TribodyTM Technology,” Located at <http://www.biotecnolcom/?tribody-technology>, last visited on Aug. 28, 2018, two pages. [cited by applicant]
Bird, R.E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,” Science 242:423-426, 7 pages. [cited by applicant]
Bloom, L. et al. (Oct. 2009). “FN3: A New Protein Scaffold Reaches the Clinic,” Drug Discovery Today 14(19-20):949-955. [cited by applicant]
Bobo, R.H. et al. (Mar. 15, 1994). “Convection-Enhanced Delivery of Macromolecules in the Brain,” Proc. Natl. Acad. Sci. USA 91(6):2076-2080. [cited by applicant]
Boerner, P. et al. (Jul. 1, 1991). “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes,” J. Immunol. 147(1):86-95. [cited by applicant]
Borden, P. et al. (Apr. 1, 1987). “Nucleotide Sequence of the cDNAs Encoding the Variable Region Heavy and Light Chains of a Myeloma Protein Specific for the Terminal Nonreducing End of Alpha(1 →6)Dextran,” PNAS 84(8):2… [cited by applicant]
Bottaro, D.P. et al. (1991). “Identification of the Hepatocyte Growth Factor Receptor as the c-met Proto-Oncogene Product,” Science 251(4995):802-804. [cited by applicant]
Bradley, P. et al. (Sep. 16, 2005). “Toward High-Resolution De Novo Structure Prediction For Small Proteins,” Science 309(5742):1868-1871, 5 pages. [cited by applicant]
Brennan, M. et al. (Jul. 5, 1985). “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G [cited by applicant]
Brooks, B.R. et al. (1983). “CHARMM: A Program For Macromolecular Energy, Minimization, and Dynamics Calculations,” J. Comput. Chem. 4(2):187-217. [cited by applicant]
Bruggemann, M. et al. (1993). “Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals,” Year in Immunol. 7:33-40. [cited by applicant]
Burbaum, J.J. et al. (1990). “Understanding Structural Relationships of Proteins of Unsolved Three-Dimensional Structure,” Proteins 7(2):99-111. [cited by applicant]
Calaycay, J. et al. (Oct. 5, 1985). “Primary Structure of a DNA- And Heparin-Binding Domain (Domain III) in Human Plasma Fibronectin,” J. Biol. Chem. 260(22):12136-12141. [cited by applicant]
Caron, P.C. et al. (1992; e-pub. Oct. 1, 1992). “Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies,” J. Exp Med. 176:1191-1195. [cited by applicant]
Carpenter et al. (Apr. 15, 2002). “A Humanized Non-FcR-binding anti-CD3 Antibody, Visilizumab, For Treatment Of Steroid-Refractory Acute Graft-Versus-Host Disease,” Blood 99(5):2712-2719. [cited by applicant]
Carter, P. et al. (Feb. 1992). “High Level [cited by applicant]
Chames, et al. (Apr. 2009). “Bispecific Antibodies For Cancer Therapy: The Light At The End Of The Tunnel?” mAbs 1(6):539-547. [cited by applicant]
Chang, et al. (May 2002). “Molecular Advances in Pretargeting Radioimmunotherapy with Bispecific Antibodies [cited by applicant]
Charman, W.N. (2000, e-pub. Aug. 2000). “Lipids, Lipophilic Drugs, and Oral Drug Delivery—Some Emerging Concepts,” Journal of Pharmaceutical Sciences 89(8):967-978. [cited by applicant]
Chatzigeorgiou, A. et al. (Dec. 2009, e-pub. Nov. 2009). “CD40/CD40L Signaling and Its Implication in Health and Disease,” Biofactors. 35(6):474-483. [cited by applicant]
Chaudhary, V.K. et al. (Feb. 1990). “A Rapid Method of Cloning Functional Variable-Region Antibody Genes in [cited by applicant]
Chetty, R. et al. (1994). “CD3: Structure, Function, and Role of Immunostaining in Clinical Practice,” J Pathol. 173(4):303-307. [cited by applicant]
Chiswell, D.J. et al. (1992). “Phage Antibodies: Will New ‘Coliclonal’ Antibodies Replace Monoclonal Antibodies?,” Trends in Biotechnology10:80-84. [cited by applicant]
Chothia, C. et al. (1987). “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol. 196(4):901-917, 18 pages. [cited by applicant]
Chothia, C. et al. (Dec. 21-28, 1989). “Conformations of Immunoglobulin Hypervariable Regions,” Nature 342(6252):877-883. [cited by applicant]
Clackson, T. et al. (Aug. 15, 1991). “Making Antibody Fragments Using Phage Display Libraries,” Nature 352(6336):624-628. [cited by applicant]
Coloma, M. J. et al. (Feb. 1997). “Design And Production Of Novel Tetravalent Bispecific Antibodies,” Nat. Biotechnol. 15:159-163. [cited by applicant]
Conrad, M.L. et al. (2007; e-pub. Jul. 25, 2007). “TCR and CD3 Antibody Cross-Reactivity in 44 Species,” Cytometry (Part A) 71A:925-933. [cited by applicant]
Cote, R.J. et al. (Apr. 1983). “Generation of Human Monoclonal Antibodies Reactive With Cellular Antigens,” Proc Natl Acad Sci USA 80:2026-2030. [cited by applicant]
Cwirla, S.E. et al. (Aug. 1990). “Peptides on Phage: A Vast Library of Peptides for Identifying Ligands,” PNAS USA 87:6378-6382. [cited by applicant]
Darke, P.L. et al. (Feb. 5, 1989). “Human Immunodeficiency Virus Protease. Bacterial Expression and Characterization of the Purified Aspartic Protease,” J. Biol. Chem. 264(4):2307-2312. [cited by applicant]
Davidson, B.L. et al. (Mar. 1993). “A Model System For in Vivo Gene Transfer into the Central Nervous System Using An Adenoviral Vector,” Nature Genetics 3:219-223. [cited by applicant]
Davies, D.R. et al. (Jul. 1990). “Antibody-Antigen Complexes,” Annual Rev. Biochem. 59:439- 473. [cited by applicant]
Davis, J.H. et al. (2010, e-pub. Feb. 4, 2010). “SEEDbodies: Fusion Proteins Based On Strand-Exchange Engineered Domain (Seed) CH3 Heterodimers In An Fc Analogue Platform For Asymmetric Binders Or Immunofusions And Bisp… [cited by applicant]
Davis, L.H. et al. (Jun. 15, 1991). “Specific 33-Residue Repeat(s) Erythrocyte Ankyrin Associate with the Anion Exchanger,” J. Biol. Chem. 266(17):11163-11169. [cited by applicant]
Dayhoff, M.O. et al. (1978). “A Model Of Evolutionary Change in Proteins,” Chapter 22 in Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC, 5(3):345-352. [cited by applicant]
Demydenko, D. et al. (Jun. 2009) “Expression Of Galectin-1 In Malignant Tumors,” Exp Oncol. 31(2):74-79. [cited by applicant]
Deyev, S.M. et al. (2008, e-pub. 2008). “Multivalency: The Hallmark Of Antibodies Used For Optimization Of Tumor Targeting By Design,” BioEssays 30:904-918. [cited by applicant]
Dietz, H. et al. (Jan. 31, 2006). “Protein Structure by Mechanical Triangulation,” Proc. Nat. Acad. Sci. USA 103(5):1244-1247. [cited by applicant]
Dodson, E.J. (Nov. 7-8, 2007). “Computational Biology: Protein Predictions,” Nature 450:176-177. [cited by applicant]
Donate, L.E. et al. (Dec. 1994). “Molecular Evolution and Domain Structure of Plasminogen-related Growth Factors (HGF/SF and HGF1/MSP),” Prat. Sci. 3(12):2378-2394. [cited by applicant]
Dong, J. et al. (Feb. 11, 2011). “Stable IgG-like Bispecific Antibodies Directed Toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity,” Journal of Biological… [cited by applicant]
Ehrlich, P.H. et al. (1980). “Isolation of an Active Heavy-Chain Variable Domain From a Homogeneous Rabbit Antibody by Cathepsin B Digestion of the Aminoethylated Heavy Chain,” Biochem 19(17):4091-4096. [cited by applicant]
Eisenfield, J. et al. (1991; e-published on Aug. 1991). “Constrained Optimization and Protein Structure Determination,” Am. J. Physiol. 261:C376-386. [cited by applicant]
Eppstein, D.A. et al. (Jun. 1985). “Biological Activity of Liposome-Encapsulated Murine Interferon γ Is Mediated by a Cell Membrane Receptor,” Proc. Natl. Acad. Sci. USA 82:3688-3692. [cited by applicant]
Fellouse, F.A. et al. (Aug. 24, 2004). “Synthetic Antibodies from a Four-Amino-Acid Code: A Dominant Role for Tyrosine in Antigen Recognition,” PNAS 101(34):12467-12472. [cited by applicant]
Fishwild, D.M. et al. (Jul. 1996). “High-Avidity Human IgG [cited by applicant]
Flaherty, D. K. (2012) Chapter 10 “Antibody Diversity, Immunology for Pharmacy” in Immunology for Pharmacy. St. Louis, Mo.: Elsevier, 12 pages. [cited by applicant]
Froimowitz, M. (Jun. 1, 1990). “The Development of Computer Simulations of the Geometries and Thermodynamics of Biological Molecules,” Biotechniques 8(6):640-644. [cited by applicant]
Geller, A.I. et al. (Aug. 1993). “Long-Term Increases in Neurotransmitter Release From Neuronal Cells Expressing a Constitutively Active Adenylate Cyclase From a Herpes Simplex Virus Type 1 Vector,” Proc Natl. Acad. Sci… [cited by applicant]
Geller, A.I. et al. (Feb. 1990). “Infection of Cultured Central Nervous System Neurons With a Defective Herpes Simplex Virus 1 Vector Results in Stable Expression of [cited by applicant]
Geller, A.I. et al. (Feb. 1995). “An HSV-1 Vector Expressing Tyrosine Hydroxylase Causes Production and Release of I-DOPA from Cultured Rat Striatal Cells,” J. Neurochem 64(2):487-496. [cited by applicant]
Gorman, C.M. et al. (Nov. 1982). “The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced Into a Variety of Eukaryotic Cells by DNA-Mediated Transfection,” Proc Natl. Acad. Sci. U.S.A. 79:6777-6… [cited by applicant]
Graham, F.L. et al. (Jul. 1977). “Characteristics of a Human Cell Line Transformed by DNA From Human Adenovirus Type 5,” J. Gen Virol. 36(1):59-74. [cited by applicant]
Green, L.L. et al. (May 1994). “Antigen-Specific Human Monoclonal Antibodies From Mice Engineered With Human Ig Heavy And Light Chain YACs,” Nature Genetics 7(1):13-21. [cited by applicant]
Grosschedl, R. et al. (Jul. 1985). “Cell-Type Specificity of Immunoglobulin Gene Expression is Regulated By at Least Three DNA Sequence Elements,” Cell 41(3):885-897. [cited by applicant]
Grosse-Hovest, L. et al. (2003). “A Recombinant Bispecific Single-Chain Antibody Induces Targeted, Supra-Agonistic CD28-Stimulation And Tumor Cell Killing,” Eur.J. Immunol. 33:1334-1340. [cited by applicant]
Gruber, M. et al. (1994). “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Gunasekaran, K, et al. (Jun. 18, 2010). “Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG,” Journal of Biological Chemistry 285(… [cited by applicant]
Guss, B. et al. (Jul. 1986). “Structure of the IgG-Binding Regions of Streptococcal Protein G,” EMBO J. 5(7):1567-1575. [cited by applicant]
Hamers-Casterman, C. et al. (Jun. 3, 1993). “Naturally Occurring Antibodies Devoid of Light Chains,” Nature 363(6428):446-448. [cited by applicant]
Hanes, J. et al. (May 1997). “In Vitro Selection and Evolution of Functional Proteins by Using Ribosome Display,” Proc Natl. Acad. Sci. U.S.A. 94:4937-4942. [cited by applicant]
Harris, W.J. (Nov. 1, 1995). “Therapeutic Monoclonals: Production of Humanized Monoclonal Antibodies for In Vivo Imaging and Therapy,” Biochem. Soc. Transactions 23(4):1035-1038. [cited by applicant]
Hein, J. (1990). “Unified Approach to Alignment and Phylogenies,” Methods in Enzymology 183:626-645. [cited by applicant]
Henikoff, S. et al. (Nov. 15, 1992). “Amino Acid Substitution Matrices from Protein Blocks,” Proc. Natl. Acad. Sci. USA 89(22):10915-10919. [cited by applicant]
Herold. K.C. et al. (Feb. 1, 2003). “Activation of Human T Cells by FcR Nonbinding Anti-CD3 mAb, HOKT3γ1 (Ala-Ala),” J. Clin. Invest. 111(3):409-418. [cited by applicant]
Higgins, D.G. et al. (1989). “Fast and Sensitive Multiple Sequence Alignments on a Microcomputer,” Comput Appl Biosci. 5(2):151-153. [cited by applicant]
Hirsch, R. et al. (Jun. 1988). “Effects of In Vivo Administration of Anti-T3 Monoclonal Antibody on T Cell Function in Mice: I. Immunosuppression if Transplantation Responses,” J. Immunol. 140(11):3766-3772. [cited by applicant]
Hochman, J. et al. (1976). “Folding and Interaction of Subunits at the Antibody Combining Site,” Biochem 15(12):2706-2710. [cited by applicant]
Holliger, P. et al. (Jul. 1993). ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences 90:6444-6448. [cited by applicant]
Holt, L.J. et al. (Nov. 2003). “Domain Antibodies: Proteins for Therapy,” Trends in Biotechnology 21(11):484-490. [cited by applicant]
Hongo, J.S. et al. (1995). “Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β [cited by applicant]
Hoogenboom, H.R. et al. (1992). “By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline Hh Gene Segments Rearranged in Vitro,” Journal of Molecular Biology 227:381-388. [cited by applicant]
Hoogenboom, H.R. et al. (Dec. 1992). “Building Antibodies from their Genes,” Immunol. Reviews 130(1):41-68. [cited by applicant]
Houdebine, L. M. (1994). “Production Of Pharmaceutical Proteins From Transgenic Animals,” Journal Of Biotechnology 34(3):269-287. [cited by applicant]
Hurle, M.R. et al. (Aug. 1994).“Protein Engineering Techniques for Antibody Humanization,” Current Opinion in Biotechnology 5:428-433. [cited by applicant]
Huse, W.D. et al. (Dec. 8, 1989). “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” Science 246(4935):1275-1281. [cited by applicant]
Huston, J.S. et al. (Aug. 1988). “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in [cited by applicant]
Hwang, K.J. et al. (Jul. 1980). “Hepatic Uptake and Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study,” Proc. Natl Acad. Sci. USA 77(7):4030-4034. [cited by applicant]
Inbar, D. et al. (Sep. 1972). “Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains,” Proc. Nat. Acad. Sci. USA 69(9):2659-2662. [cited by applicant]
International Preliminary Report on Patentability Chapter I mailed Sep. 18, 2018 for International Application No. PCT/CN2017/076816, filed on Mar. 15, 2017, 7 pages. [cited by applicant]
International Preliminary Report on Patentability Chapter I mailed Mar. 9, 2021 for International Application No. PCT/CN2019/104680, filed on Sep. 6, 2019, 6 pages. [cited by applicant]
International Preliminary Report on Patentability issued Jun. 16, 2021, for Patent Application No. PCT/CN2018/123108 filed on Dec. 24, 2018, 6 pages. [cited by applicant]
International Preliminary Report on Patentability issued Jun. 16, 2021, for Patent Application No. PCT/CN2019/127433 filed on Dec. 23, 2019, 5 pages. [cited by applicant]
International Preliminary Report on Patentability mailed Nov. 28, 2013, for Patent Application No. PCT/US2012/038177 filed on May 16, 2012, 7 pages. [cited by applicant]
International Search Report and Written Opinion from the International Searching Authority mailed Sep. 24, 2019, for International Patent Application No. PCT/CN2018/123108 filed Dec. 24, 2018, 15 pages. [cited by applicant]
International Search Report and Written Opinion from the International Searching Authority mailed Mar. 18, 2020, for International Patent Application No. PCT/CN2019/127433 filed Dec. 23, 2019, 13 pages. [cited by applicant]
International Search Report mailed Nov. 14, 2012, Patent Application No. PCT/US2012/038177 filed on May 16, 2012, 10 pages. [cited by applicant]
International Search Report mailed on Dec. 17, 2019 for International Patent Application No. PCT/CN2019/104680, filed on Sep. 6, 2019, 7 pages. [cited by applicant]
International Search Report mailed on Jun. 21, 2017 for International Patent Application No. PCT/CN2017/076816, filed on Mar. 15, 2017, 6 pages. [cited by applicant]
Jakobovits, A. et al. (Mar. 18, 1993) “Germ-line Transmission and Expression of a Human-derived Yeast Artificial Chromosome,” Nature 362:255-258. [cited by applicant]
Jakobovits, A. et al. (Mar. 1993). “Analysis of Homozygous Mutant Chimeric Mice: Deletion of The Immunoglobulin Heavy-chain Joining Region Blocks B-Cell Development and Antibody Production,” Proceedings of the National … [cited by applicant]
Jansen, F.K. et al. (Feb. 1982). “Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity,” Immunological Reviews 62(1):185-216. [cited by applicant]
Jiang, T. et al. (Dec. 21, 2004; e-pub Dec. 15, 2004). “Tumor Imaging by Means of Proteolytic Activation of Cell-Penetrating Peptides,” Proc. Natl. Acad. Sci. U.S.A. 101(51):17867-17872. [cited by applicant]
Johnson, et al. (2010, e-pub. Apr. 9, 2020). “Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion,” J Mol. Biol. 399:436-449. [cited by applicant]
Johnson, G. et al. (2003). “The Kabat Database and a Bioinformatics Example,” Methods in Molecular Biology 248:1-25. (Abstract Only, 1 page). [cited by applicant]
Jones, P.T. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,” Nature 321:522-525. [cited by applicant]
Kaplitt, M.G. et al. (Oct. 1994). “Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain,” Nature Genetics 8:148-154. [cited by applicant]
Kappel, C.A. et al. (Oct. 1, 1992). “Regulating Gene Expression In Transgenic Animals,” Current Opinion In Biotechnology 3(5):548-553. [cited by applicant]
Killen J.A. et al. (Nov. 1984) “Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates,” J. Immunol. 133(5):2549-2553. [cited by applicant]
Kini, R.M. et al. (1991, e-pub May 21, 2012). “Molecular Modeling of Proteins: A Strategy for Energy Minimization by Molecular Mechanics in the AMBER Force Field,” J. Biomol. Struct. Dyn. 9(3):475-488, 16 pages. [cited by applicant]
Kipriyanov, S.M. et al. (1999). “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J Mal. Biol., 293:41-56. [cited by applicant]
Kipriyanov, S.M. and Le Gall, F. (2004). “Recent Advances In The Generation Of Bispecific Antibodies For Tumor Immunotherapy,” Curr. Opin. Drug Discov. Devel. 7:233-242. [cited by applicant]
Kipriyanov, S.M. et al. (Dec. 31, 1998). “Bispecific CD3xCD19 Diabody for T Cell-Mediated LYSIS of Malignant Human B Cells,” Int. J. Cancer 77:763-772. [cited by applicant]
Klimka, A. et al. (Jun. 20, 2000). “Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,” British Journal of Cancer 83(2):252-260. [cited by applicant]
Koch-Nolte, F. et al. (2007; e-pub. Jun. 15, 2007). “Single Domain Antibodies From Llama Effectively and Specifically Block T Cell Ecto-ADP-Ribosyltransferase ART2.2 in vivo,” FASEB J. 21:3490-3498. [cited by applicant]
Kohler, G. et al. (Aug. 7, 1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256:495-497. [cited by applicant]
Koide, A. et al. (2007). “Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain,” Methods Mol. Biol. 352:95-109. [cited by applicant]
Koide, A. et al. (Dec. 11, 1998). “The Fibronectin Type III Domain as a Scaffold For Novel Binding Proteins,” J. Mol. Biol. 284(4):1141-1151. [cited by applicant]
Kontermann, R.E. (Jan. 2005). “Recombinant bispecific antibodies for cancer therapy,” Acta Pharmacol. Sin. 26(1):1-9. [cited by applicant]
Kostelny, S.A. et al. (Mar. 1, 1992). “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553. [cited by applicant]
Kozbor, D. et al. (Dec. 1984). “A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies,” The Journal of Immunology 133(6):3001-3005. [cited by applicant]
Kozbor, D. et al. (Mar. 1983). “The Production of Monoclonal Antibodies From Human Lymphocytes, ” Immunology Today 4(3):72-79. [cited by applicant]
La Rocca, G. et al. (Apr. 5, 2004; e-pub. Mar. 16, 2004). “Zymographic Detection and Clinical Correlations of MMP-2 And MMP-9 in Breast Cancer Sera,” British J. of Cancer 90(7):1414-1421. [cited by applicant]
Laplanche, L.A. et al. (Nov. 25, 1986). “Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Sp duplexes, [d(GGSAATTCC)]2, derived from diastereomeric O… [cited by applicant]
Lavasani, S. et al. (2007; e-pub. Dec. 14, 2006). “Monoclonal Antibody against T-Cell Receptor αβ Induces Self-Tolerance in Chronic Experimental Autoimmune Encephalomyelitis,” Scandinavian Journal of Immunology 65(1):39… [cited by applicant]
Lavie, G. et al. (Apr. 1, 2000). “Inhibition of the CD8+ T Cell-Mediated Cytotoxicity Reaction By Hypericin: Potential For Treatment Of T Cell-Mediated Diseases,” International Immunology 12(4):479-486. [cited by applicant]
Le Gal La Salle, G. et al. (Feb. 12, 1993). “An Adenovirus Vector for Gene Transfer Into Neurons and Glia in the Brain,” Science 259(5097):988-990. [cited by applicant]
Lee, C.V. et al. (2004). “Bivalent Antibody Phage Display Mimics Natural Immunoglobulin,” Journal of Immunological Methods 284(1-2):119-132. [cited by applicant]
Lee, C.V. et al. (2004). “High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold,” Journal of Molecular Biology 340:1073-1093. [cited by applicant]
Li, J. et al. (Mar. 7, 2006). “Human Antibodies for Immunotherapy Development Generated via a Human B Cell Hybridoma Technology,” PNAS 103(10):3557-3562. [cited by applicant]
Lindmark, R. et al. (Aug. 12, 1983). “Binding of Immunoglobulins To Protein A and Immunoglobulin Levels in Mammalian Sera,” J. Immunol. Meth. 62(1):1-13. [cited by applicant]
Liu, A.Y. et al. (May 1987). “Chimeric Mouse-Human IgG1 Antibody That Can Mediate Lysis of Cancer Cells,” Proc Natl Acad Sci U S A. 84(10):3439-3443. [cited by applicant]
Liu, A.Y. et al. (Nov. 15, 1987). “Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biologic Activity,” J. Immunol. 139(10):3521-3526. [cited by applicant]
Liu, R. et al. (Jun. 5, 2010). “Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-IBB Ligand/anti-CD20 Fusion Proteins and Anti-CD3/anti-CD20 Diabodies,” J Immunother.… [cited by applicant]
Lonberg, N. et al. (1995). “Human Antibodies from Transgenic Mice,” International Reviews of Immunology. 13(1):65-93. [cited by applicant]
Lonberg, N. et al. (Apr. 28, 1994). “Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368:856-859. [cited by applicant]
Lu, D. et al. (2002). “Fab-scFv Fusion Protein: An Efficient Approach to Production of Bispecific Antibody Fragments,” Journal of Immunological Methods 267:213-226. [cited by applicant]